Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML

Blood (2022) 139 (8): 1208–1221.

https://doi.org/10.1182/blood.2021011354

Published: 2022

Includes: Supplemental data

Journal Articles

Comparative Outcomes and Molecular Response Predictors of IDH1/2-Mutated Adult Acute Myeloid Leukemia (AML) Patients (Pts) after Frontline Treatment with Intensive Induction Chemotherapy (IC), Targeted Inhibitors, or Hypomethylating Agents (HMA) (Alliance)

Blood (2021) 138 (Supplement 1): 226.

https://doi.org/10.1182/blood-2021-152838

Published: 2021

Journal Articles

Prevalence of Inherited Cancer Predisposition Mutations in a Cohort of Older AML Patients Enrolled on the Beat AML Master Trial

Blood (2019) 134 (Supplement_1): 373.

https://doi.org/10.1182/blood-2019-131925

Published: 2019

Journal Articles

Clinical Utility of a Multi-Gene Next-Generation Sequencing Myeloid Panel in an Academic Hematology Practice

Pedro G Vianna, BSc,MD, Richard D. Press, MD PhD, Henning Stehr, PhD, Fei Yang, MD, Linda Gojenola, James L Zehnder, Jason Gotlib, MD MS

Blood (2019) 134 (Supplement_1): 1408.

https://doi.org/10.1182/blood-2019-124445

Published: 2019

Journal Articles

Framework to Identify and Prioritize Candidate Inherited Myeloid Malignancy Germline Variants Leveraging the BEAT AML Cohort

Daniel Bottomly, Nicola Long, Fei Yang, MD, Tiffany Lee, MD, Uma Borate, MD, Beth Wilmot, PhD, Adam S DuVall, MD, Andrea Monteblanco, BS, Karina Thiel-Klare, Gabby Dewson, BA, Richard D. Press, MD PhD, Cristina E. Tognon, Brian J. Druker, Jeffrey W. Tyner, Shannon K. McWeeney, PhD, Anupriya Agarwal, PhD

Blood (2019) 134 (Supplement_1): 1407.

https://doi.org/10.1182/blood-2019-132224

Published: 2019

Journal Articles

Characterization of the Genomic Landscape of BCR-ABL1 Kinase-Independent Mechanisms of Resistance to ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Blood (2016) 128 (22): 1119.

https://doi.org/10.1182/blood.V128.22.1119.1119

Published: 2016

Journal Articles

A Novel CSF3R Mutation Uncovers the Importance of Membrane-Proximal N-Glycosylation for Receptor Regulation

Seamus B Hughes, David Spiciarich, Richard D. Press, Sarah L Thompson, Jerald P. Radich, Carolyn Bertozzi, Stephen T. Oh, MD PhD, Julia E. Maxson, PhD

Blood (2016) 128 (22): 3141.

https://doi.org/10.1182/blood.V128.22.3141.3141

Published: 2016

Journal Articles

Mutations Modifying Risk in NPM1+ AML

Jessica Leonard, MD, Jennifer Dunlap, MD, Tanaya L Neff, Andrea Warrick, Fei Yang, Richard D. Press, MD PhD, Brian J. Druker, MD, Elie Traer, MD, PhD

Blood (2015) 126 (23): 2592.

https://doi.org/10.1182/blood.V126.23.2592.2592

Published: 2015

Journal Articles

Clinical Evaluation of Xpert® BCR-ABL Ultra, an Automated and Standardized Cartridge-Based Assay for the Quantification of BCR-ABL1

Michael J. Mauro, MD, Richard D. Press, MD PhD, David S. Snyder, MD, Qin Huang, MD PhD, Javier Pinilla-Ibarz, Dahui Qin, MD PhD, Christina Lockwood, PhD, Jacqueline E. Payton, MD PhD, Geoffrey L. Uy, MD, Matt E. Kalaycio, MD, Ramon V. Tiu, MD BS, Vivian Oehler, MD, Gwo-Jen Day, PhD, Wendy Wong, Michael P. Bates, MD, Jerald P. Radich

Blood (2015) 126 (23): 5170.

https://doi.org/10.1182/blood.V126.23.5170.5170

Published: 2015

Journal Articles

TNFα facilitates clonal expansion of JAK2 V617F positive cells in myeloproliferative neoplasms

Angela G. Fleischman, Karl J. Aichberger, Samuel B. Luty, Thomas G. Bumm, Curtis L. Petersen, Shirin Doratotaj, Kavin B. Vasudevan, Dorian H. LaTocha, Fei Yang, Richard D. Press, Marc M. Loriaux, Heike L. Pahl, Richard T. Silver, Anupriya Agarwal, Thomas O'Hare, Brian J. Druker, Grover C. Bagby, Michael W. Deininger

Blood (2011) 118 (24): 6392–6398.

https://doi.org/10.1182/blood-2011-04-348144

Published: 2011

Includes: Supplemental data

Journal Articles

ERG, BAALC, and MN1 RNA Levels Are Correlatively Over-Expressed, and Relate to Risk-Defining Prognostic Mutations in Intermediate-Risk Acute Myeloid Leukemia

Fei Yang, Franklin Moore, M.D., Ph.D., Dean Westberry, Miriam Hough, Julie Partain, William H Fleming, MD, PhD, Tibor Kovacsovics, MD, Richard D. Press, MD, PhD

Blood (2011) 118 (21): 1471.

https://doi.org/10.1182/blood.V118.21.1471.1471

Published: 2011

Journal Articles

The BCR-ABL 35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia

Thomas O'Hare, Matthew S. Zabriskie, Christopher A. Eide, Anupriya Agarwal, Lauren T. Adrian, Huihong You, Amie S. Corbin, Fei Yang, Richard D. Press, Victor M. Rivera, Julie Toplin, Stephane Wong, Michael W. Deininger, Brian J. Druker

Blood (2011) 118 (19): 5250–5254.

https://doi.org/10.1182/blood-2011-05-349191

Published: 2011

Includes: Supplemental data

Journal Articles

Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA

Blood (2010) 116 (22): e111–e117.

https://doi.org/10.1182/blood-2010-06-291641

Published: 2010

Includes: Supplemental data

Journal Articles

Comparison of Different Laboratory Methods for Quantification of BCR-ABL Kinase Domain Mutations In CML Patients Undergoing Tyrosine Kinase Inhibitor Therapy

Richard D. Press, MD, PhD, Fei Yang

Blood (2010) 116 (21): 2760.

https://doi.org/10.1182/blood.V116.21.2760.2760

Published: 2010

Journal Articles

Clinical Outcomes In Patients with Chronic Myelogenous Leukemia (CML) and the BCR-ABL 35 Base Pair (bp) Intron 8 Insertion Mutation.

Ellin Berman, MD, Jorge Cortes, MD, Hagop M. Kantarjian, MD, Thomas O'Hare, PhD, Christopher Eide, BS, Richard D. Press, MD, PhD, Brian J Druker, MD, Cyrus V. Hedvat, MD, PhD

Blood (2010) 116 (21): 3408.

https://doi.org/10.1182/blood.V116.21.3408.3408

Published: 2010

Journal Articles

BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib

Daniel W. Sherbenou, Oliver Hantschel, Ines Kaupe, Stephanie Willis, Thomas Bumm, Lalita P. Turaga, Thoralf Lange, Kim-Hien Dao, Richard D. Press, Brian J. Druker, Giulio Superti-Furga, Michael W. Deininger

Blood (2010) 116 (17): 3278–3285.

https://doi.org/10.1182/blood-2008-10-183665

Published: 2010

Includes: Supplemental data

Journal Articles

Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib

Richard D. Press, Stephanie G. Willis, Jennifer Laudadio, Michael J. Mauro, Michael W. N. Deininger

Blood (2009) 114 (13): 2598–2605.

https://doi.org/10.1182/blood-2008-08-173674

Published: 2009

Journal Articles

Determining the Rise in BCR-ABL RNA That Optimally Predicts a Kinase Domain Mutation in Patients with CML on Imatinib.

Richard D. Press, MD, PhD, Stephanie G Willis, Jennifer Laudadio, Michael J. Mauro, MD, Michael W.N. Deininger, MD

Blood (2008) 112 (11): 1108.

https://doi.org/10.1182/blood.V112.11.1108.1108

Published: 2008

Journal Articles

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials

Susan Branford, Linda Fletcher, Nicholas C. P. Cross, Martin C. Müller, Andreas Hochhaus, Dong-Wook Kim, Jerald P. Radich, Giuseppe Saglio, Fabrizio Pane, Suzanne Kamel-Reid, Y. Lynn Wang, Richard D. Press, Kevin Lynch, Zbigniew Rudzki, John M. Goldman, Timothy Hughes

Blood (2008) 112 (8): 3330–3338.

https://doi.org/10.1182/blood-2008-04-150680

Published: 2008

Journal Articles

BCR-ABL Transcript Levels at Time of Complete Cytogenetic Remission Achieved after Salvage with Dasatinib or Nilotinib.

Michael J. Mauro, MD, Richard D. Press, MD, PhD, Michael W. Deininger, MD, PhD, Brian J. Druker, MD

Blood (2007) 110 (11): 1945.

https://doi.org/10.1182/blood.V110.11.1945.1945

Published: 2007

NARROW

Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML

Comparative Outcomes and Molecular Response Predictors of IDH1/2-Mutated Adult Acute Myeloid Leukemia (AML) Patients (Pts) after Frontline Treatment with Intensive Induction Chemotherapy (IC), Targeted Inhibitors, or Hypomethylating Agents (HMA) (Alliance)

Prevalence of Inherited Cancer Predisposition Mutations in a Cohort of Older AML Patients Enrolled on the Beat AML Master Trial

Clinical Utility of a Multi-Gene Next-Generation Sequencing Myeloid Panel in an Academic Hematology Practice

Framework to Identify and Prioritize Candidate Inherited Myeloid Malignancy Germline Variants Leveraging the BEAT AML Cohort

Characterization of the Genomic Landscape of BCR-ABL1 Kinase-Independent Mechanisms of Resistance to ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

A Novel CSF3R Mutation Uncovers the Importance of Membrane-Proximal N-Glycosylation for Receptor Regulation

Mutations Modifying Risk in NPM1+ AML

Clinical Evaluation of Xpert® BCR-ABL Ultra, an Automated and Standardized Cartridge-Based Assay for the Quantification of BCR-ABL1

TNFα facilitates clonal expansion of JAK2 V617F positive cells in myeloproliferative neoplasms

ERG, BAALC, and MN1 RNA Levels Are Correlatively Over-Expressed, and Relate to Risk-Defining Prognostic Mutations in Intermediate-Risk Acute Myeloid Leukemia

The BCR-ABL 35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia

Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA

Comparison of Different Laboratory Methods for Quantification of BCR-ABL Kinase Domain Mutations In CML Patients Undergoing Tyrosine Kinase Inhibitor Therapy

Clinical Outcomes In Patients with Chronic Myelogenous Leukemia (CML) and the BCR-ABL 35 Base Pair (bp) Intron 8 Insertion Mutation.

BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib

Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib

Determining the Rise in BCR-ABL RNA That Optimally Predicts a Kinase Domain Mutation in Patients with CML on Imatinib.

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials

BCR-ABL Transcript Levels at Time of Complete Cytogenetic Remission Achieved after Salvage with Dasatinib or Nilotinib.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only